Scholarlink

Background <p>Intralesional bleomycin is a safe, minimally invasive therapy for head and neck vascular anomalies. We conducted a 12-month prospective study at a tertiary care center in India to assess bleomycin sclerotherapy in patients with cervicofacial hemangiomas and vascular malformations.</p> Methods <p>Thirty-one patients (18&#xa0;F, 13&#xa0;M; median age ~ 8 years) were enrolled over one year. Lesions included with 12 infantile hemangiomas, 12 low-flow malformations (8 venous, 4 lymphatic), and 7 AVMs(arteriovenous malformations) underwent ultrasound- or palpation-guided intralesional bleomycin injections (0.5 mL per session, typically 1–2 sessions) under local or general anesthesia. Outcomes at the last follow-up (up to 12 months) were classified as complete resolution, marked improvement (&gt; 50% size reduction), or no response.</p> Results <p>At last follow-up (up to 12 months), 19 of 31 patients (61%) achieved complete lesion resolution, 7 (23%) had marked improvement, and 5 (16%) had no significant change. All 12 hemangiomas responded (10 complete, 2 partial). Among 12 low-flow malformations, 9 fully resolved and 2 improved (1 unchanged). None of 7 AVMs fully resolved: 3 showed partial shrinkage and 4 had minimal change. No treated lesion progressed or recurred during follow-up. Bleomycin was well tolerated: no serious systemic toxicity (e.g. pulmonary fibrosis) occurred. Adverse effects were mild and transient (mostly local pain and low-grade fever); one small mucosal ulcer and two transient skin hyperpigmentation patches healed with conservative care.</p> Conclusion <p>Bleomycin sclerotherapy yielded high rates of lesion regression in hemangiomas and low-flow malformations, with minimal morbidity, whereas AVMs showed only modest improvement. These findings support intralesional bleomycin as an effective, well-tolerated minimally invasive option for managing head and neck vascular anomalies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intralesional Bleomycin Sclerotherapy for Head and Neck Vascular Anomalies (Hemangiomas and Malformations): A Prospective Tertiary-Center Study

  • 期刊论文

  • 发表日期：

    2026年3月3日

查看全文
  • Asef Ahmad Wani,
  • Owais Makhdoomi,
  • Majid Ul Islam Masoodi,
  • Ayaz Rehman

摘要

Background

Intralesional bleomycin is a safe, minimally invasive therapy for head and neck vascular anomalies. We conducted a 12-month prospective study at a tertiary care center in India to assess bleomycin sclerotherapy in patients with cervicofacial hemangiomas and vascular malformations.

Methods

Thirty-one patients (18 F, 13 M; median age ~ 8 years) were enrolled over one year. Lesions included with 12 infantile hemangiomas, 12 low-flow malformations (8 venous, 4 lymphatic), and 7 AVMs(arteriovenous malformations) underwent ultrasound- or palpation-guided intralesional bleomycin injections (0.5 mL per session, typically 1–2 sessions) under local or general anesthesia. Outcomes at the last follow-up (up to 12 months) were classified as complete resolution, marked improvement (> 50% size reduction), or no response.

Results

At last follow-up (up to 12 months), 19 of 31 patients (61%) achieved complete lesion resolution, 7 (23%) had marked improvement, and 5 (16%) had no significant change. All 12 hemangiomas responded (10 complete, 2 partial). Among 12 low-flow malformations, 9 fully resolved and 2 improved (1 unchanged). None of 7 AVMs fully resolved: 3 showed partial shrinkage and 4 had minimal change. No treated lesion progressed or recurred during follow-up. Bleomycin was well tolerated: no serious systemic toxicity (e.g. pulmonary fibrosis) occurred. Adverse effects were mild and transient (mostly local pain and low-grade fever); one small mucosal ulcer and two transient skin hyperpigmentation patches healed with conservative care.

Conclusion

Bleomycin sclerotherapy yielded high rates of lesion regression in hemangiomas and low-flow malformations, with minimal morbidity, whereas AVMs showed only modest improvement. These findings support intralesional bleomycin as an effective, well-tolerated minimally invasive option for managing head and neck vascular anomalies.